Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction

Camilleri, Michael; Malagelada, Juan–R.; Abell, Thomas L.; Brown, Manuel L.; Hench, Victoria S.; Zinsmeister, Alan R.

doi:10.1016/0016-5085(89)90893-7

Cited by 95 publications

(85 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Responsiveness to treatment Responsiveness of SBTT to treatment was shown in studies of the effect of cisapride in patients with gastroparesis and chronic intestinal dysmotility 60,61 and of tegaserod in patients with IBS-constipation. 62 Clinical significance Identification of delayed SBTT has been shown to alter both initial diagnosis and clinical management.…”

Section: Study Performance the Test Involves Ingestion Of Either A LImentioning

confidence: 99%

Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies

Rao¹,

Camilleri²,

Hasler³

et al. 2010

Neurogastroenterology &Amp; Motility

322

296

View full text Add to dashboard Cite

Background Disorders of gastrointestinal (GI) transit and motility are common, and cause either delayed or accelerated transit through the stomach, small intestine or colon, and affect one or more regions. Assessment of regional and/or whole gut transit times can provide direct measurements and diagnostic information to explain the cause of symptoms, and plan therapy. Purpose Recently, several newer diagnostic tools have become available. The American and European Neurogastroenterology and Motility Societies undertook this review to provide guidelines on the indications and optimal methods for the use of transit measurements in clinical practice. This was based on evidence of validation including performance characteristics, clinical significance, and strengths of various techniques. The tests include measurements of: gastric emptying with scintigraphy, wireless motility capsule, and 13 C breath tests; small bowel transit with breath tests, scintigraphy, and wireless motility capsule; and colonic transit with radioopaque markers, wireless motility capsule, and scintigraphy. Based on the evidence, consensus recommendations are provided for each technique and for the evaluations of regional and whole gut transit. In summary, tests of gastrointestinal transit are available and useful in the evaluation of patients with symptoms suggestive of gastrointestinal dysmotility, since they can provide objective diagnosis and a rational approach to patient management.

show abstract

Section: Study Performance the Test Involves Ingestion Of Either A LImentioning

confidence: 99%

Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies

Rao¹,

Camilleri²,

Hasler³

et al. 2010

Neurogastroenterology &Amp; Motility

322

296

View full text Add to dashboard Cite

show abstract

“…The main causes of death are TPN-related complications, surgery-related complications, and post-transplantation complication, together with septic shock of GI origin. A variety of clinical, histological and manometric parameters have been found to be predictive of a poor clinical outcome in adult patients, including myopathy and decreased contractile activity [2,50,52,53,[55][56][57][58][59][60] . MNGIE has a particularly poor prognosis with slowly progressive evolution and death around 40 years of age [11] .…”

Section: Natural Historymentioning

confidence: 99%

“…Some prokinetics seem to be more effective than others: metoclopramide, domperidone, bethanechol or neostigmine are often used, but with only limited success, while cisapride, that is currently available only in some parts of the world, has been reported to exert positive effects [60,[64][65][66][67] . Two controlled trials including CIPO patients described positive effects of cisapride in accelerating g astric emptying [60] and improving symptoms [66] .…”

Section: Pharmacological Therapymentioning

confidence: 99%

See 1 more Smart Citation

Chronic intestinal pseudo-obstruction

Antonucci¹,

Fronzoni²,

Cogliandro³

et al. 2008

WJG

189

238

View full text Add to dashboard Cite

“…Cisapride stimulates gastro-intestinal motility by facilitating acetylcholine release from the myenteric plexus via a 5-HT 4 receptor mechanism [31]. A number of studies have evaluated the effects of cisapride on gastric emptying in diabetic gastroparesis [32, 33, 34, 35, 36, 37, 38, 39, 40, 41]. While in the majority of these studies cisapride has been shown to accelerate gastric emptying, in others the results were equivocal or negative [37, 38, 41].…”

Section: Introductionmentioning

confidence: 99%

Relationship between the Effects of Cisapride on Gastric Emptying and Plasma Glucose Concentrations in Diabetic Gastroparesis

Horowitz

Jones²,

Harding³

et al. 2002

Digestion

View full text Add to dashboard Cite

Background/Aims: The effect of erythromycin on gastric emptying is attenuated during hyperglycaemia. The aim of this study was to determine in patients with diabetic gastroparesis whether the effect of cisapride on gastric emptying of solids and liquids is influenced by the plasma glucose concentration. Methods: Nineteen patients with type 1 diabetes mellitus, who had delayed gastric emptying of solids and/or liquids, were studied. On 2 separate days, each patient received cisapride (20 mg) or placebo orally 60 min before scintigraphic measurement of gastric emptying of a mixed solid (ground beef) and liquid (dextrose) meal. The plasma glucose concentrations were measured at –5, 30, 60, 90, and 120 min during each gastric emptying measurement. Results: Cisapride accelerated both solid (retention at 100 min 43 ± 4 vs. 69 ± 4%, p < 0.001) and liquid (T₅₀ 27 ± 2 vs. 39 ± 2 min, p < 0.001) gastric emptying. The mean plasma glucose level was not significantly different after placebo when compared with cisapride (19.5 ± 1.1 vs. 18.2 ± 1.0 mmol/l). The change in the 50% emptying time (T₅₀) for liquid, but not solid, emptying was related (r = 0.55, p = 0.01) to the change in the plasma glucose AUC from 0 to 30 min between the placebo and cisapride tests, i.e., the acceleration was greater if the plasma glucose concentration was relatively less during the gastric emptying test performed on cisapride. Conclusion: The effect of cisapride on gastric emptying, at least that of liquids, in patients with diabetic gastroparesis appears to be dependent on the plasma glucose concentration.

show abstract

Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction

Cited by 95 publications

References 12 publications

Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies

Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies

Chronic intestinal pseudo-obstruction

Relationship between the Effects of Cisapride on Gastric Emptying and Plasma Glucose Concentrations in Diabetic Gastroparesis

Contact Info

Product

Resources

About